JP2009544600A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544600A5 JP2009544600A5 JP2009519999A JP2009519999A JP2009544600A5 JP 2009544600 A5 JP2009544600 A5 JP 2009544600A5 JP 2009519999 A JP2009519999 A JP 2009519999A JP 2009519999 A JP2009519999 A JP 2009519999A JP 2009544600 A5 JP2009544600 A5 JP 2009544600A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- ethyl
- prodrug
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 63
- 150000001875 compounds Chemical class 0.000 claims description 37
- 239000000651 prodrug Substances 0.000 claims description 23
- 229940002612 prodrug Drugs 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 23
- 239000012453 solvate Substances 0.000 claims description 23
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 125000004076 pyridyl group Chemical group 0.000 claims description 11
- DUOODFOGRNRUEN-UHFFFAOYSA-N 1-[2-(4-fluorophenyl)ethyl]-3,7-dioxo-1,4-diazepane-5-carboxamide Chemical compound FC1=CC=C(C=C1)CCN1CC(NC(CC1=O)C(=O)N)=O DUOODFOGRNRUEN-UHFFFAOYSA-N 0.000 claims description 5
- XDWKEYTUCRXDLE-UHFFFAOYSA-N n-(2-amino-2-oxoethyl)-1,4-bis[2-(4-fluorophenyl)ethyl]-n-[2-(4-methoxyphenyl)ethyl]-3,7-dioxo-1,4-diazepane-5-carboxamide Chemical compound C1=CC(OC)=CC=C1CCN(CC(N)=O)C(=O)C1N(CCC=2C=CC(F)=CC=2)C(=O)CN(CCC=2C=CC(F)=CC=2)C(=O)C1 XDWKEYTUCRXDLE-UHFFFAOYSA-N 0.000 claims description 5
- 102100020695 Ubiquitin-conjugating enzyme E2 N Human genes 0.000 claims description 4
- 101710192923 Ubiquitin-conjugating enzyme E2 N Proteins 0.000 claims description 4
- ACGSDDRFGAYPIN-UHFFFAOYSA-N n-(2-amino-2-oxoethyl)-1-[2-(2,4-dichlorophenyl)ethyl]-4-[2-(4-fluorophenyl)ethyl]-n-[2-(4-methoxyphenyl)ethyl]-3,7-dioxo-1,4-diazepane-5-carboxamide Chemical compound C1=CC(OC)=CC=C1CCN(CC(N)=O)C(=O)C1N(CCC=2C=CC(F)=CC=2)C(=O)CN(CCC=2C(=CC(Cl)=CC=2)Cl)C(=O)C1 ACGSDDRFGAYPIN-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- XYRPFVHWGSDUIR-UHFFFAOYSA-N n-(2-amino-2-oxoethyl)-n-[2-(2,4-dichlorophenyl)ethyl]-1,4-bis[2-(4-fluorophenyl)ethyl]-3,7-dioxo-1,4-diazepane-5-carboxamide Chemical compound C1C(=O)N(CCC=2C=CC(F)=CC=2)CC(=O)N(CCC=2C=CC(F)=CC=2)C1C(=O)N(CC(=O)N)CCC1=CC=C(Cl)C=C1Cl XYRPFVHWGSDUIR-UHFFFAOYSA-N 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000001207 fluorophenyl group Chemical group 0.000 claims description 2
- -1 imidazolyl Propyl Chemical group 0.000 claims 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 6
- 230000002757 inflammatory effect Effects 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 4
- 230000037353 metabolic pathway Effects 0.000 claims 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 230000007170 pathology Effects 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 201000002481 Myositis Diseases 0.000 claims 2
- 229910002651 NO3 Inorganic materials 0.000 claims 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 2
- 150000003857 carboxamides Chemical class 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 231100000024 genotoxic Toxicity 0.000 claims 2
- 230000001738 genotoxic effect Effects 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004344 phenylpropyl group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000006513 pyridinyl methyl group Chemical group 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 108050006400 Cyclin Proteins 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000003945 NF-kappa B Human genes 0.000 claims 1
- 108010057466 NF-kappa B Proteins 0.000 claims 1
- 208000008636 Neoplastic Processes Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000005141 Otitis Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 101100427180 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RAD6 gene Proteins 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 101150016610 UBC2 gene Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000019258 ear infection Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- AJCKFJHSSNFUHO-UHFFFAOYSA-N NC(CN(CCc1ccccn1)C(CC(C(N(CCc(cc1)ccc1F)C1)=O)N(CCc(cc2)ccc2F)C1=O)=O)=O Chemical compound NC(CN(CCc1ccccn1)C(CC(C(N(CCc(cc1)ccc1F)C1)=O)N(CCc(cc2)ccc2F)C1=O)=O)=O AJCKFJHSSNFUHO-UHFFFAOYSA-N 0.000 description 2
- YIJSHNQUGRJHKU-UHFFFAOYSA-N CC1N(C)C(CCN(CC(N)=O)C(C(CC(N(CCc(ccc(Cl)c2)c2Cl)C2)=O)N(CCc(cc3)ccc3F)C2=O)=O)C=CC1 Chemical compound CC1N(C)C(CCN(CC(N)=O)C(C(CC(N(CCc(ccc(Cl)c2)c2Cl)C2)=O)N(CCc(cc3)ccc3F)C2=O)=O)C=CC1 YIJSHNQUGRJHKU-UHFFFAOYSA-N 0.000 description 1
- 101100427169 Homo sapiens UBE2V1 gene Proteins 0.000 description 1
- RPJCCCUEHHPESH-UHFFFAOYSA-N NC(CN(CCc1ncccc1)C(C(CC(N(CCc(cc1)ccc1F)C1)=O)N(CCc(cc2)ccc2F)C1=O)=O)=O Chemical compound NC(CN(CCc1ncccc1)C(C(CC(N(CCc(cc1)ccc1F)C1)=O)N(CCc(cc2)ccc2F)C1=O)=O)=O RPJCCCUEHHPESH-UHFFFAOYSA-N 0.000 description 1
- 102100038467 Ubiquitin-conjugating enzyme E2 variant 1 Human genes 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940125890 compound Ia Drugs 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200601933A ES2293834B1 (es) | 2006-07-20 | 2006-07-20 | Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas. |
| ESP200601933 | 2006-07-20 | ||
| PCT/ES2007/000120 WO2008009758A1 (es) | 2006-07-20 | 2007-03-07 | Compuestos con actividad inhibidora de las interacciones ubc13-uev, composiciones farmacéuticas y aplicaciones terapéuticas |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009544600A JP2009544600A (ja) | 2009-12-17 |
| JP2009544600A5 true JP2009544600A5 (OSRAM) | 2011-05-19 |
| JP5203363B2 JP5203363B2 (ja) | 2013-06-05 |
Family
ID=38956569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009519999A Expired - Fee Related JP5203363B2 (ja) | 2006-07-20 | 2007-03-07 | Ｕｂｃ１３−ｕｅｖ相互作用を阻害することができる化合物、医薬組成物および治療的使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8252786B2 (OSRAM) |
| EP (1) | EP2045251B1 (OSRAM) |
| JP (1) | JP5203363B2 (OSRAM) |
| CN (1) | CN101506196B (OSRAM) |
| AU (1) | AU2007275073B2 (OSRAM) |
| CA (1) | CA2658327C (OSRAM) |
| ES (1) | ES2293834B1 (OSRAM) |
| MX (1) | MX2009000672A (OSRAM) |
| WO (1) | WO2008009758A1 (OSRAM) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1912679A4 (en) | 2005-06-15 | 2009-07-29 | Massachusetts Inst Technology | AMINOUS LIPIDS AND ITS USES |
| WO2010053572A2 (en) | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| NZ598125A (en) * | 2009-07-30 | 2014-05-30 | Salvat Lab Sa | Apaf-1 inhibitor compounds |
| RS58405B1 (sr) | 2009-12-01 | 2019-04-30 | Translate Bio Inc | Stereoidni derivati za isporuku irnk u humanim genetskim oboljenjima |
| US9193827B2 (en) | 2010-08-26 | 2015-11-24 | Massachusetts Institute Of Technology | Poly(beta-amino alcohols), their preparation, and uses thereof |
| EP2688566A4 (en) * | 2011-03-23 | 2014-09-10 | Univ Indiana Res & Tech Corp | THERAPEUTIC AGENTS AGAINST CANCER |
| CA2831392C (en) | 2011-03-28 | 2020-04-28 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
| JP6184945B2 (ja) | 2011-06-08 | 2017-08-23 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | ｍＲＮＡ送達のための脂質ナノ粒子組成物および方法 |
| PE20181541A1 (es) | 2011-10-27 | 2018-09-26 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco |
| US20130236504A1 (en) * | 2012-03-06 | 2013-09-12 | Medical University Of South Carolina | Delivery System for Enhancing Drug Efficacy |
| US20150267192A1 (en) | 2012-06-08 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| WO2014028487A1 (en) | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
| EP2970955B1 (en) | 2013-03-14 | 2018-11-14 | Translate Bio, Inc. | Methods for purification of messenger rna |
| WO2014153052A2 (en) | 2013-03-14 | 2014-09-25 | Shire Human Genetic Therapies, Inc. | Cftr mrna compositions and related methods and uses |
| US9315472B2 (en) | 2013-05-01 | 2016-04-19 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
| BR112016009014B1 (pt) | 2013-10-22 | 2024-02-06 | Translate Bio, Inc | USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE |
| CN112656954A (zh) | 2013-10-22 | 2021-04-16 | 夏尔人类遗传性治疗公司 | 用于递送信使rna的脂质制剂 |
| MX2016005239A (es) | 2013-10-22 | 2016-08-12 | Shire Human Genetic Therapies | Tratamiento con acido ribonucleico mensajero para la fenilcetonuria. |
| JP6295767B2 (ja) | 2014-03-25 | 2018-03-20 | 富士通株式会社 | スイッチ装置、情報処理システムおよびスイッチ装置の制御方法 |
| SG11201608725YA (en) | 2014-04-25 | 2016-11-29 | Shire Human Genetic Therapies | Methods for purification of messenger rna |
| EP3587409B8 (en) | 2014-05-30 | 2022-07-13 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
| KR102511554B1 (ko) | 2014-06-24 | 2023-03-16 | 샤이어 휴먼 지네틱 테라피즈 인크. | 핵산의 전달용 입체화학적으로 풍부한 조성물 |
| WO2016004202A1 (en) | 2014-07-02 | 2016-01-07 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
| LT3310764T (lt) | 2015-06-19 | 2023-06-12 | Massachusetts Institute Of Technology | Alkenilu pakeisti 2,5-piperazindionai ir jų panaudojimas kompozicijose, skirtose agento pristatymui į subjektą ar ląstelę |
| AU2018224326B2 (en) | 2017-02-27 | 2024-01-04 | Translate Bio, Inc. | Novel codon-optimized CFTR mRNA |
| IL270631B2 (en) | 2017-05-16 | 2024-03-01 | Translate Bio Inc | Treatment of cystic fibrosis through the administration of mRNA with an optimal codon encoding ctfr |
| CN112930396B (zh) | 2018-08-24 | 2024-05-24 | 川斯勒佰尔公司 | 用于纯化信使rna的方法 |
| US20200157157A1 (en) | 2018-11-21 | 2020-05-21 | Translate Bio, Inc. | TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR |
| EP4516300A3 (en) * | 2019-06-14 | 2025-08-06 | Children's Hospital Medical Center | Rational therapeutic targeting of oncogenic immune signaling states in myeloid malignancies via the ubiquitin conjugating enzyme ube2n |
| KR20220017075A (ko) | 2020-08-04 | 2022-02-11 | 삼성전자주식회사 | 홈 화면을 복원하는 방법 및 이를 적용한 전자 장치 |
| US20250214975A1 (en) * | 2022-05-19 | 2025-07-03 | Ohio State Innovation Foundation | Peptidyl flavor modifiers |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4234295A1 (de) * | 1992-10-12 | 1994-04-14 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| CA2281224A1 (en) * | 1997-02-15 | 1998-08-20 | Proscript, Inc. | Treatment of infarcts through inhibition of nf-kappab |
| AU2001281392A1 (en) * | 2000-08-08 | 2002-02-18 | The Government Of The United States Of America, As Represented By The Secretary Of Health And Human | Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway |
| ES2169690B1 (es) * | 2000-10-06 | 2004-03-16 | Diverdrugs Sl | Trimeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotoxicas, y composiciones que los contienen. |
| TW200538149A (en) | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
| ES2296484B1 (es) * | 2005-11-23 | 2009-04-01 | Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe (90%) | Composicion farmaceutica para inhibir la apoptosis. |
-
2006
- 2006-07-20 ES ES200601933A patent/ES2293834B1/es not_active Expired - Fee Related
-
2007
- 2007-03-07 CA CA2658327A patent/CA2658327C/en not_active Expired - Fee Related
- 2007-03-07 US US12/309,429 patent/US8252786B2/en not_active Expired - Fee Related
- 2007-03-07 CN CN2007800313305A patent/CN101506196B/zh not_active Expired - Fee Related
- 2007-03-07 MX MX2009000672A patent/MX2009000672A/es active IP Right Grant
- 2007-03-07 AU AU2007275073A patent/AU2007275073B2/en not_active Ceased
- 2007-03-07 JP JP2009519999A patent/JP5203363B2/ja not_active Expired - Fee Related
- 2007-03-07 WO PCT/ES2007/000120 patent/WO2008009758A1/es not_active Ceased
- 2007-03-07 EP EP07730361.8A patent/EP2045251B1/en not_active Not-in-force
-
2012
- 2012-07-23 US US13/555,804 patent/US8785430B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009544600A5 (OSRAM) | ||
| JP2020524719A5 (OSRAM) | ||
| EP3555074B1 (en) | Aminopyrazoles as selective janus kinase inhibitors | |
| US20190269783A1 (en) | Compounds and methods to sensitize cancer cells to tyrosine kinase inhibitors | |
| JP2009513703A5 (OSRAM) | ||
| RU2010128107A (ru) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp | |
| JP2008528467A5 (OSRAM) | ||
| JP2015500212A5 (OSRAM) | ||
| JP2010514689A5 (OSRAM) | ||
| US11691973B2 (en) | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors | |
| JP2013056930A5 (OSRAM) | ||
| JP2016528197A5 (OSRAM) | ||
| ES2617878T3 (es) | Inhibidores de tubulina basados en la pirazina | |
| CN115215847A (zh) | 一类kras-sos1抑制剂、其制备方法及其应用 | |
| JP2012526107A5 (OSRAM) | ||
| JP2020503376A5 (OSRAM) | ||
| TW201002688A (en) | Pharmaceutical compounds | |
| CN115697988A (zh) | 3,4-二氢异喹啉类化合物及其应用 | |
| AU2011271480B2 (en) | Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity | |
| WO2017070718A4 (en) | Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of cyp17a1 and cyp19a1 | |
| US20210220331A1 (en) | Inhibitors of ires-mediated protein synthesis | |
| Jiao et al. | Design, synthesis, and evaluation of benzoheterocyclic-containing derivatives as novel HDAC1 inhibitors | |
| JP2013510899A5 (OSRAM) | ||
| Song et al. | Discovery of Novel Bifunctional Agents as Potent TRK Inhibitors and Degraders against xDFG Mutation Resistance | |
| JP2024047569A (ja) | Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン |